China Resources Medical Holdings Company Limited (the Company, together with its subsidiaries, the Group) announced that Mr. CHENG Libing (Mr. CHENG) has resigned, with effect from February 27, 2023, as an executive Director of the Company and an authorized representative of the Company (Authorized Representative) due to personal pursuit. Mr. CHENG has confirmed that he has no disagreement with the Board and that there is no matter in respect of his resignations which needs to be brought to the attention of the shareholders of the Company (the Shareholders) and The Stock Exchange of Hong Kong Limited. The Board announced that Mr. FU Tingmei (Mr. FU) has been appointed as an independent non-executive Director with effect from February 27, 2023.

Mr. FU, aged 56, currently serves as an independent non-executive director of the following companies which are listed on the Stock Exchange: China Resources Pharmaceutical Group Limited, Guotai Junan International Holdings Limited, Postal Savings Bank of China Co. Ltd. and COFCO Joycome Foods Limited. Mr. FU was an independent non-executive director of Beijing Enterprises Holdings Limited from July 2008 to June 2017 and an independent non-executive director of CPMC Holdings Limited, a company listed on the Stock Exchange from June 2008 to July 2019.

Mr. FU has over 30 years of experience in investment, finance, law and business management. Mr. FU holds a master's degree in law and a Ph.D. degree in law from London University, the United Kingdom. Mr. FU has entered into a letter of appointment with the Company for a term from February 27, 2023 to February 26, 2026, which can be terminated by either party by giving to the other party not less than one month's notice in writing.

Pursuant to the articles of association of the Company, Mr. FU will hold office as an independent non-executive Director until the next annual general meeting of the Company and will be subject to the retirement by rotation and re-election at that meeting. The Board announced that Mr. YU Hai (Mr. YU) has been appointed as an executive Director of the Company with effect from February 27, 2023. Mr. YU, aged 55, is currently the general manager of China Resources Health Group Limited, and served as the vice chairman and senior vice general manager of China Resources Health Group Limited from January 2020 to February 2023 and as the chairman of Liaoning Healthcare Industry Group Co.

Ltd. from July 2018 to January 2020. Mr. YU worked in Benxi Municipal Government, Liaoning Province from July 2008 to July 2018, and served as the deputy mayor of Benxi City etc. Prior to that, Mr. YU held various positions at government departments including the deputy director of the Social Development Division of the Department of Science & Technology of Liaoning Province, the deputy director of the High-tech Development and Industrialization Division of the Department of Science & Technology of Liaoning Province, the deputy director of the Bureau of Science and Technology of Nagchu District, the Tibet Autonomous Region, and the principal officer of the Industrial and Social Development Division, the Scientific and Technological Commission of Liaoning Province etc.

Mr. YU holds a doctor of science degree in pharmaceutical affairs management from the School of Pharmacy, Shenyang Pharmaceutical University. Mr. YU has entered into a service agreement with the Company for a term of three years commencing from February 27, 2023, which can be terminated by either party by giving to the other party not less than one month's notice in writing. The aforesaid proposal on the emolument of Mr. YU was determined by the Board, upon recommendation by the Remuneration Committee with reference to the prevailing market situation and his duties and responsibilities to the Group.

The company announced that Mr. LEE Kar Chung Felix has resigned as a member of the audit committee of the Company (Audit Committee), Mr. HU Hui has resigned as a member of the Remuneration Committee and Mr. FU Tingmei has been appointed as a member of the Audit Committee and a member of the Remuneration Committee with effect from February 27, 2023.